NextCure Historical Financial Ratios
| NXTC Stock | USD 0.57 0.04 6.56% |
NextCure is lately reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate NextCure financial condition quickly.
NextCure |
About NextCure Financial Ratios Analysis
NextCureFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate NextCure investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on NextCure financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across NextCure history.
NextCure Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing NextCure stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on NextCure sales, a figure that is much harder to manipulate than other NextCure multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from NextCure's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into NextCure current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.At present, NextCure's Book Value Per Share is projected to increase based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.35, whereas Free Cash Flow Yield is projected to grow to (1.82).
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 17.97 | 16.38 | 7.5 | 14.3 | Net Debt To EBITDA | 0.28 | 0.11 | 0.42 | 0.39 |
NextCure fundamentals Correlations
Click cells to compare fundamentals
NextCure Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NextCure fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 1.02 | 0.71 | 0.23 | 0.28 | 0.33 | 0.35 | |
| Book Value Per Share | 10.67 | 8.45 | 6.04 | 4.11 | 2.34 | 4.5 | |
| Free Cash Flow Yield | (0.17) | (0.36) | (1.43) | (1.7) | (1.91) | (1.82) | |
| Operating Cash Flow Per Share | (1.63) | (2.07) | (1.94) | (1.9) | (1.46) | (1.53) | |
| Capex To Depreciation | 2.09 | 0.33 | 0.51 | 0.22 | 0.17 | 0.16 | |
| Pb Ratio | 1.02 | 0.71 | 0.23 | 0.28 | 0.33 | 0.35 | |
| Free Cash Flow Per Share | (1.89) | (2.16) | (2.02) | (1.93) | (1.48) | (1.55) | |
| Roic | (0.13) | (0.33) | (0.4) | (0.56) | (0.84) | (0.88) | |
| Net Income Per Share | (1.21) | (2.51) | (2.5) | (2.25) | (1.99) | (2.09) | |
| Payables Turnover | 0.0119 | 2.21 | 1.05 | 1.58 | 1.42 | 1.49 | |
| Cash Per Share | 10.3 | 7.95 | 5.76 | 3.89 | 2.45 | 2.33 | |
| Pocfratio | (6.68) | (2.89) | (0.73) | (0.6) | (0.53) | (0.55) | |
| Capex To Operating Cash Flow | (0.16) | (0.0412) | (0.0393) | (0.0155) | (0.0116) | (0.0122) | |
| Pfcf Ratio | (5.76) | (2.78) | (0.7) | (0.59) | (0.52) | (0.55) | |
| Days Payables Outstanding | 30.6K | 164.84 | 347.89 | 230.85 | 265.48 | 252.2 | |
| Income Quality | 1.23 | 0.82 | 0.72 | 0.84 | 0.73 | 0.58 | |
| Roe | (0.11) | (0.3) | (0.41) | (0.55) | (0.85) | (0.81) | |
| Ev To Operating Cash Flow | (6.02) | (2.68) | (0.36) | (0.48) | 0.0248 | 0.0261 | |
| Pe Ratio | (9.04) | (2.39) | (0.56) | (0.51) | (0.39) | (0.41) | |
| Return On Tangible Assets | (0.11) | (0.29) | (0.38) | (0.49) | (0.69) | (0.72) | |
| Ev To Free Cash Flow | (5.2) | (2.57) | (0.35) | (0.47) | 0.0245 | 0.0258 | |
| Net Debt To E B I T D A | 0.77 | 0.19 | 0.28 | 0.11 | 0.42 | 0.39 | |
| Current Ratio | 27.89 | 34.48 | 17.97 | 16.38 | 7.5 | 14.3 | |
| Tangible Book Value Per Share | 10.67 | 8.45 | 6.04 | 4.11 | 2.34 | 4.5 | |
| Shareholders Equity Per Share | 10.67 | 8.45 | 6.04 | 4.11 | 2.34 | 4.5 | |
| Debt To Equity | 0.016 | 0.0118 | 0.0425 | 0.0577 | 0.0787 | 0.0826 | |
| Capex Per Share | 0.26 | 0.0855 | 0.0763 | 0.0295 | 0.0169 | 0.0161 | |
| Graham Net Net | 9.83 | 7.63 | 5.15 | 3.4 | 1.9 | 3.76 | |
| Interest Debt Per Share | 0.34 | 0.13 | 0.002788 | 0.26 | 0.24 | 0.18 | |
| Debt To Assets | 0.0144 | 0.0113 | 0.0387 | 0.0516 | 0.0637 | 0.0669 | |
| Enterprise Value Over E B I T D A | (7.16) | (2.36) | (0.28) | (0.43) | 0.0186 | 0.0196 | |
| Price Earnings Ratio | (9.04) | (2.39) | (0.56) | (0.51) | (0.39) | (0.41) | |
| Price Book Value Ratio | 1.02 | 0.71 | 0.23 | 0.28 | 0.33 | 0.35 | |
| Price Earnings To Growth Ratio | 0.21 | (0.0222) | 1.41 | 0.0506 | 0.0335 | 0.0318 | |
| Days Of Payables Outstanding | 30.6K | 164.84 | 347.89 | 230.85 | 265.48 | 252.2 | |
| Price To Operating Cash Flows Ratio | (6.68) | (2.89) | (0.73) | (0.6) | (0.53) | (0.55) | |
| Price To Free Cash Flows Ratio | (5.76) | (2.78) | (0.7) | (0.59) | (0.52) | (0.55) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.